医学
氨氯地平
血压
多沙唑嗪
赖诺普利
比索洛尔
耐受性
利尿剂
阿替洛尔
安慰剂
交叉研究
药品
抗高血压药
药理学
内科学
依那普利
β受体阻滞剂
血管紧张素转换酶
不利影响
心力衰竭
替代医学
病理
作者
Alison Deary,Anne L. Schumann,Helen Murfet,Stephen Haydock,Roger Foo,Morris J. Brown
标识
DOI:10.1097/00004872-200204000-00037
摘要
Objective Hypertension guidelines recommend initial treatment with a β-blocker or diuretic and adding the other drug where blood pressure is not controlled. We hypothesized that systematic rotation through the major classes of antihypertensive drugs would demonstrate substantial differences in the pattern of an individual patient's response, and suggest a more rational approach to choosing best treatment. Design Thirty-four young hypertensives (age 28–55, median 47) rotated in a double-blind, Latin-square, crossover fashion through 6 weeks of treatment each with amlodipine, doxazosin, lisinopril, bisoprolol, bendrofluazide and placebo. Blood pressure was measured at each visit. 'Best' drug, defined by efficacy and tolerability, was repeated at the end. Results Rotation doubled the number of patients reaching target blood pressure (systolic < 140 mmHg) on one drug (P = 0.03). All five drugs were represented among the 'best' drugs. In six patients, the blood pressure on 'best' drug was at least 10 mmHg lower than on any other. Response to the 'best' drug was highly correlated (r = 0.79) with its previous administration. By contrast, there were only weak correlations between responses to pairs of drugs, except for angiotensin-converting enzyme (ACE) inhibitor (A) with β-blocker (B), and calcium blocker (C) with diuretic (D) – each r = 0.71, P< 0.005). In these young patients, the majority of patients (23/34) responded best to a drug suppressing the renin system (A and B). Conclusions Patients vary reproducibly in their response to initial treatment, and switching among drugs can increase the efficacy of monotherapy. The results support an AB/CD scheme for choosing therapy, in which the first drug is taken from one of these pairs, and uncontrolled patients switch to one of the other pair.
科研通智能强力驱动
Strongly Powered by AbleSci AI